Immunotherapy in Cancer: Hits and Misses, but Charging Ahead – Medscape
Medscape |
Immunotherapy in Cancer: Hits and Misses, but Charging Ahead
Medscape After the many success of immunotherapy in various cancer types over the last few years, recent news of failures has come as a bit of a shock. It was a bad day for AstraZeneca in July when stock shares plummeted by more than 16% —the highly … |
